A practical target for hormone therapy for transgender women (MTF) is to decrease testosterone levels to the normal female range (30–100 ng/dl) without supra- physiological levels of estradiol (<200 pg/ml) by administering an

MtFトランスジェンダーに対してはエストロゲンの投与が一般的です。効果としては、肌がすべすべになった、胸が膨らんできた、脂肪がついてきたといった外見的な変化。それから、涙もろくなった、体温調整が聞きづらくなったなど内面的な

Feminizing hormone therapy involves taking medicine to block the action of the hormone testosterone. It also includes taking the hormone estrogen. Estrogen lowers the amount of testosterone the body makes. It also triggers the development of feminine secondary sex characteristics.

The following information has been produced by the Nottingham Centre for Transgender Health (NCTH) and is designed to inform healthcare professionals of the recommended hormonal treatment for trans and non-binary people.

However, studies and surveys suggest a prevalence of male‐to‐female (MTF) transsexuality of around 0.001% (), to 0.6% (Joseph 2017), depending on time and location. Transition from one gender to another is a critical phase with specific treatment, that differs fundamentally from later maintenance care, after the gender transition ...